Clinical Trial Update: A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated capecitabine (Xeloda) as first-line chemotherapy in participants with metastatic nasopharyngeal cancer and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Cancer

Drugs mentioned

• Capecitabine (Xeloda) (Capecitabine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Nasopharyngeal Cancer | Phase 2 | Status: COMPLETED